The entire landscape of hospital-based clinical trials dramatically changed when COVID-19 singlehandedly stopped the global recruitment of ongoing cardiovascular trials. Heart failure clinical trials were already subject to factors such as regional variation in clinical practice, trial implementation, and patient characteristics, which drive event rate and treatment effect size assumptions key to demonstrating clinical benefit. Learn how CCS and SCIRENT applied agile cardiovascular trial management practices to handle this crisis.
Dr. Marvin Konstam (CCS), Patrica Wedge (CCS), and Elvis Tahirovic (SCIRENT) will explore the best practices Cardiovascular Clinical Sciences (CCS) and SCIRENT employed to navigate the pandemic landscape to reactivate global heart failure clinical trials rapidly and safely for successful recruitment of ongoing studies.
- Jumpstarting Enrollment: How a regional rolling recruitment approach and early identification of critical barriers to reactivation (i.e., safety, staffing, regulatory) restarted recruitment
- OUS Recruiting: How to avoid geographical disparities in patient population, recruitment, and conduct
- Safeguard Data Integrity: How centralized clinical operations and data-driven analytical review processes minimizes regional variations and ensures balanced study populations
- Q&A with the team – responding to your questions!
SCIRENT is a full-service contract research organization (CRO) specialized in cardiovascular trial services. Our services cover the whole range of clinical trial services. Our CRO was founded in 2012 with the vision to help clients develop innovative medical drugs and devices for patients with cardiovascular diseases. Our dedicated team of experienced clinical and regulatory professionals can provide faster and more efficient service from our trial sites in Europe and beyond.
About CCS Trials
CCS was founded in 1997 by two cardiologists with a single vision: better clinical trial management through more effective integration of thought leader, site, and patient perspectives. For over three decades CCS has led groundbreaking cardiovascular research from single-center phase I studies to 10,000 patient pivotal trials, navigating complexity with ease.